Indirect Assay Patents (Class 435/7.95)
-
Patent number: 8153381Abstract: Provided are methods and devices for determining the strain of a pathogen in a sample.Type: GrantFiled: April 28, 2008Date of Patent: April 10, 2012Assignee: Alere Scarborough, Inc.Inventors: William J. Palin, Nathan Turner
-
Patent number: 8133718Abstract: An analytical strip and a detecting method using the analytical strip are provided. The analytical strip includes a substrate having a channel thereon. The channel has a first region, a second region and a third region, which are arranged successively. A first antibody is localized in the first region. A saccharide and a peroxidase are localized in the first or second region. A second antibody for recognizing a different epitope of an identical antigen with the first antibody is immobilized in the second region. A substrate reagent including a saccharide oxidase is localized in the third region.Type: GrantFiled: April 29, 2009Date of Patent: March 13, 2012Assignee: Actherm IncInventors: Yi-Jen Wu, Chih-Wei Hsieh, Wen-Pin Hsieh
-
Publication number: 20120040382Abstract: Isolated, monoclonal, human, anti-?-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an A? polypeptide comprising A?(21-37) shield A?(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.Type: ApplicationFiled: April 5, 2011Publication date: February 16, 2012Applicant: Philipps-Universitaet MarburgInventors: Richard DODEL, Michael BACHER, Michael PRZYBYLSKI, Raluca STEFANESCU, Marilena MANEA
-
Patent number: 8114612Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction are disclosed. Troponin I and T exist in various conformations and the ratios of monomeric troponin I and T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed are systems to determine the presence of a troponin form or a group of troponin forms in whole blood, serum or plasma samples. Disclosed is a method for improving the recovery of troponin I or T from a surface used in immunoassays. Also disclosed are antibodies which recognize unbound troponin forms, the forms of troponin in binary complexes, the ternary complex of troponin I, T and C, and the conformations of troponin I having intramolecularly oxidized and reduced cysteines.Type: GrantFiled: January 7, 2011Date of Patent: February 14, 2012Assignee: Alere San Diego, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 8110374Abstract: The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention is also directed to the use of the AT1 receptor or functionally analogous peptides or proteins in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in such biological materials, e.g. in body fluids or tissues.Type: GrantFiled: May 13, 2002Date of Patent: February 7, 2012Assignee: Cell Trend GmbHInventors: Kai Schulze-Forster, Harald Heidecke
-
Patent number: 8110406Abstract: [PROBLEMS] To reduce the amount of, for example, a capturing antibody to be employed without lowering detection sensitivity. At the same time, to enable the achievement of intense color development or light emission in a determination area even in the case where only a small amount of a labeled antibody is accumulated. To lower the detection limit in the sandwich method. To enlarge the dynamic range in the competition method. [MEANS FOR SOLVING PROBLEMS] A method of analyzing a test substance by an immunological analysis method by using the test substance, a support having a determination area, on which one member selected from a capturing antibody capable of binding specifically to the test substance and a capturing antigen capable of binding specifically to the test substance has been immobilized, and a labeled antibody capable of binding specifically to the test substance, wherein a label having a sensitizing effect has been immobilized on the determination area of the support.Type: GrantFiled: November 27, 2006Date of Patent: February 7, 2012Assignees: Japan Advanced Institute of Science and Technology, Bio Device Technologies Co., Ltd.Inventors: Eiichi Tamiya, Naoki Nagatani, Teruko Yui, Tatsurou Endou, Ryou Tanaka
-
Patent number: 8105798Abstract: This invention relates to methods for identifying agents useful for treatment of diseases and pathological conditions affected by Retinoid X Receptor apoptosis. The invention also relates to methods for treating diseases and pathological conditions affected by RXR apoptosis. The invention includes compositions that are useful in the study and treatment of diseases and pathological conditions affected by RXR apoptosis.Type: GrantFiled: August 13, 2004Date of Patent: January 31, 2012Assignee: The Burnham InstituteInventors: Xiao-kun Zhang, Xihua Cao, Wen Liu
-
Publication number: 20120009608Abstract: The invention provides a method for monitoring the progression of a myeloproliferative disease, particularly Polycythemia Vera (PV) and Essential Thrombocythemia (ET), or the response to pharmacological treatment with JAK2 inhibitors in a patient diagnosed positive for the same disease, or a method for predicting thrombotic events in a patient affected by the same myeloproliferative diseases, based on the measurement of PTX3 concentration in a blood, plasma or serum sample.Type: ApplicationFiled: July 8, 2010Publication date: January 12, 2012Applicants: AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO, HUMANITAS MIRASOLE S.p.A.Inventors: Barbara BOTTAZZI, Alberto Mantovani, Tiziano Barbui, Alessandro Rambaldi
-
Patent number: 8093012Abstract: A method of in situ immunohistochemical analysis of a biological sample is provided. The method allows for the multiplex and simultaneous detection of multiple antigens, including multiple nuclear antigens, in a tissue sample.Type: GrantFiled: October 13, 2006Date of Patent: January 10, 2012Assignee: Aureon Laboratories, Inc.Inventors: Stefan Hamann, Michael Donovan, Mark Clayton, Angeliki Kotsianti
-
Patent number: 8093010Abstract: The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.Type: GrantFiled: October 29, 2009Date of Patent: January 10, 2012Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 8084224Abstract: A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.Type: GrantFiled: April 5, 2010Date of Patent: December 27, 2011Assignee: Alere San Diego, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 8084225Abstract: Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and neuroimaging, and are directed to risk assessment, prognosis, diagnosis and treatment of TIA and stroke on an emergency basis in the emergency room.Type: GrantFiled: June 13, 2006Date of Patent: December 27, 2011Assignee: CIS Biotech, Inc.Inventor: Svetlana A. Dambinova
-
Patent number: 8071322Abstract: The invention provides a method of identifying an antigen that is present in different amounts in two different samples. In general, the methods involve generating a first and second distinguishably labeled population of antibodies that reactive to the two samples, contacting the first and second labeled populations of antibodies with a plurality of antigens; and identifying any resultant antigens that are differentially bound by the first and second populations of antibodies. The antigens may be on the surface of cells e.g., animal cells, or on a solid support. Once identified, the nucleic acid encoding an antigen of interest may be identified and sequenced to reveal the identity of the antigen of interest. Kits for performing the methods are also provided. The methods find most use in medical and research applications, in particular, for identifying cell surface targets for immunotherapy and drug discovery.Type: GrantFiled: November 10, 2003Date of Patent: December 6, 2011Assignee: Epitomics, Inc.Inventor: Dongxiao Zhang
-
Publication number: 20110275536Abstract: The application discloses Quiescin Q6 as a new biomarker for acute heart failure; methods for predicting, diagnosing and/or prognosticating acute heart failure based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods.Type: ApplicationFiled: January 28, 2010Publication date: November 10, 2011Applicant: Pronota N.V.Inventor: Koen Kas
-
Patent number: 8053206Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: April 13, 2009Date of Patent: November 8, 2011Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Patent number: 8039226Abstract: The present invention dedicates to detect nephritis in early stage of either primary or secondary nephritis using an anti NC1 monoclonal antibody. The present invention dedicates to provide useful information for diagnosis of renal function to detect NC1 by immunofluorescent stain method in renal biopsy section obtained at early stage where immunoglobulins do not deposit yet in renal GBM etc, or by antigen-antibody reaction in urine or serum specimens. Furthermore, the present invention comprises to utilize for therapeutic use.Type: GrantFiled: February 15, 2005Date of Patent: October 18, 2011Inventors: Tsukao Yokoyama, Toshiyuki Imasawa
-
Patent number: 8030007Abstract: A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to SEQ ID NO: 6 polypeptide or a truncated peptide comprising an epitope of SEQ ID NO: 6 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.Type: GrantFiled: March 3, 2011Date of Patent: October 4, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: A. Said El Shami, Bruce Campbell, Dennis Sustarsic, Niver Sahakian
-
Publication number: 20110212853Abstract: A method of monitoring treatment of an inflammatory disease or an inflammatory associated disease with the use of the ratio of N-terminal pyroglutamate modified MCP-1 (MCP-1 N1pE):total concentration of MCP-1 within a biological sample as a biomarker, and a method for determining the proportion of N-terminal pyroglutamate modified MCP-1 in relation to the total concentration of MCP-1 in biological samples. Also disclosed are a diagnostic kit and a method for screening a glutaminyl cyclase (QC) inhibitor or measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor.Type: ApplicationFiled: February 18, 2011Publication date: September 1, 2011Applicant: PROBIODRUG AGInventors: Holger Cynis, Martin Kleinschmidt, Kathrin Gans, Jens-Ulrich Rahfeld, Hans-Ulrich Demuth, Nadine Taudte
-
Patent number: 8008094Abstract: As a result of investigating the optimum conditions of methods for immobilizing proteins that interact with sugar chains onto a substrate, it was revealed that coating the surface of a slide glass with GTMS enables immobilization at a higher S/N ratio than conventionally possible. Moreover, by using a substrate to which a rubber with a number of holes was affixed to form a number of reaction vessels, and further by spotting lectins onto the substrate and washing with PBST, the weak interactions between sugar chains and lectins were successfully detected with improved sensitivity. In addition, by introducing an evanescent excitation-type scanner, it became possible to detect the interactions between lectins and sugar chains without washing away the probe solution.Type: GrantFiled: December 24, 2004Date of Patent: August 30, 2011Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Jun Hirabayashi, Atsushi Kuno, Sachiko Nakamura, Noboru Uchiyama
-
Patent number: 8003333Abstract: The present invention provides an improved method of diagnosing a subject having received an organ transplant with Acute Cellular Rejection (ACR). The method comprises obtaining a biological sample from the subject, detecting an amount of at least one protein indicative of ACR in the sample, and comparing the amount of the protein in the sample to a control, wherein a difference between the amount of the protein in the sample relative to the control indicates the subject has or is developing ACR. The difference can be an increase or a decrease. In one version the biological sample comprises a serum sample, and the transplanted organ is selected from a heart, kidney, liver, bone marrow, pancreas, eye, lung or skin. A kit and methods of treating a subject having an organ transplant for ACR and treating an immune suppressed subject are also provided.Type: GrantFiled: September 22, 2008Date of Patent: August 23, 2011Assignee: MAYO Foundation for Medical Education and ResearchInventor: Michael R. Charlton
-
Patent number: 7998753Abstract: It is an object of the present invention to provide a measurement kit for developing a first developing solution and a second developing solution from different directions to suppress background noise, and an immunochromatography kit. The present invention provides a measurement kit, which comprises a first developing member for supplying a first developing solution and a second developing member for supplying a second developing solution, wherein the developing direction of the first developing solution is allowed to intersect with the developing direction of the second developing solution, so that development is carried out by developing the first and second developing solutions in different developing directions, and a water absorbent portion is established on the downstream of the developing directions.Type: GrantFiled: November 28, 2008Date of Patent: August 16, 2011Assignee: Fujifilm CorporationInventors: Hiroyuki Chiku, Junichi Katada, Hideyuki Karaki, Hiroki Terada
-
Patent number: 7989167Abstract: A method for diagnosing the presence of hereditary spastic paraplegia (HSP) or predicting the risk of developing HSP in a human subject, comprising detecting the presence or absence of a defect in a gene encoding a polypeptide comprising the sequence of FIG. 9 (SEQ ID NO: 19), in a nucleic acid sample of the subject, whereby the detection of the defect is indicative that the subject has or is at risk of developing HSP.Type: GrantFiled: November 13, 2007Date of Patent: August 2, 2011Assignees: Val-Chum L.P., The Royal Institution for the Advancement of Learning/McGill University, Universite de MontrealInventors: Guy A. Rouleau, Paul Valdmanis, Inge Meijer, Pierre Drapeau, Patrick Dion
-
Publication number: 20110177537Abstract: The present invention provides diagnostic in vitro methods as well as kits and devices to be used in the methods of the present invention for diagnosis or prognosis of a pathologic condition characterized by the presence/absence of an endogenous hormone and/or hormone analog(s) thereof involved in diabetes or metabolic syndrome. The methods comprise a quantitative separation of at least those analytes of interest whose common presence interferes with measuring the presence/absence or concentration of one of the analytes of interest by a subsequent analytical method.Type: ApplicationFiled: April 29, 2009Publication date: July 21, 2011Applicant: BECTON, DICKINSON AND COMPANYInventors: Mikkel Nissum, Christoph Eckerskorn, Andreas Pfuetzner, Thomas Forst
-
Patent number: 7964370Abstract: An analytical strip and a detecting method using the analytical strip are provided. The analytical strip includes a substrate having a channel thereon. The channel has a first region, a second region and a third region, which are connected sequentially. A first antibody is localized in the first region. A saccharide and a peroxidase are localized in the first or second region. A second antibody for recognizing a different epitope of an identical antigen with the first antibody is immobilized in the second region. An optical substrate and a substrate reagent including a saccharide oxidase are localized in the third region.Type: GrantFiled: October 17, 2008Date of Patent: June 21, 2011Assignee: Actherm IncInventors: Yi-Jen Wu, Wen-Pin Hsieh, Chih-Wei Hsieh
-
Patent number: 7960101Abstract: Division arrested cells are used in screening assays to determine the effect of a substance of interest on the cells. The division arrested cells can be used in drug screening assays, signal transduction assays, and are especially useful in large scale, high throughput assays.Type: GrantFiled: January 11, 2010Date of Patent: June 14, 2011Assignee: Life Technologies CorporationInventors: Thomas Livelli, Zhong Zhong, Mark Federici, Mei Cong
-
Patent number: 7955804Abstract: A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, selected from A-FABP, E-FABP, PGP 9.5, GFAP, Prostaglandin D synthase, Neuromodulin, Neurofilament L, Calcyphosine, RNA binding regulatory subunit, Ubiquitin fusion degradation protein 1 homolog, Nucleoside diphosphate kinase A, Glutathione S tranferase P, Cathepsin D, DJ-1 protein, Peroxiredoxin 5 and Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) in a sample of body fluid taken from the subject.Type: GrantFiled: June 16, 2005Date of Patent: June 7, 2011Assignee: Electrophoretics LimitedInventors: Denis F. Hochstrasser, Jean-Charles Sanchez, Pierre Lescuyer, Laure Allard
-
Patent number: 7955867Abstract: In the present invention cells are placed in a multiwell plate and grown. When the assay is to be performed, one uses gravity to wash away any unbound ligands rather than vacuum or centrifugation. The cells are then examined to detect the bound ligand. To perform the washing step(s) the plate is placed into a carrier plate having open wells in register with the wells of the filter plate or one may use a wicking device or an underdrain attached to the bottom of the filter plate. Sufficient wash liquid is added to allow for filtration by the effect of gravity to occur. Cells are retained within the wells at a rate of 4 times that of other rapid methods.Type: GrantFiled: January 18, 2008Date of Patent: June 7, 2011Assignee: Millipore CorporationInventor: Jun Y. Park
-
Patent number: 7947466Abstract: Fluorescence based screening assays are provided that allow for the for identification of agents that selectively bind to a ligand-gated ion channel (LGIC) such as a nicotinic acetylcholine receptor (nAChR). Also provided are methods for identifying agents that selectively bind to a neuronal-type nAChR by detecting binding of the agent to an Aplysia AChBP, which is representative of a neuronal-type nAChR. In addition, compositions and kits for performing such methods are provided.Type: GrantFiled: September 11, 2004Date of Patent: May 24, 2011Inventors: Scott B. Hansen, Palmer Taylor, Zoran Radic
-
Patent number: 7943334Abstract: The present invention provides an immunological detection method that can detect milk allergens, allergens of albumen, flour, buckwheat and peanut with high sensitivity in foods containing these allergens regardless they are denatured/native, and a detection kit to be used therefor. It is a method for detecting allergens by using 2 or more monoclonal antibodies recognizing native and denatured milk allergens, native and denatured albumen allergens, native and denatured flour allergens, native and denatured buckwheat allergens, and native and denatured peanut allergens, using asl casein which is the main protein of milk casein, ?-lactoglobulin which is the main protein of whey, ovalubumin and ovomucoid which are main proteins of albumen, gliadin which is the main protein of flour, protein with a molecular weight of 24 kDa and 76 kDa which are main proteins of buckwheat, and Ara h1 which is the main protein of peanut as an index.Type: GrantFiled: March 4, 2005Date of Patent: May 17, 2011Assignee: Prima Meat Packers, Ltd.Inventors: Masanobu Akimoto, Shigeki Katou, Makoto Namioka
-
Patent number: 7935497Abstract: A method of detecting a protease in a sample. The method comprises providing an analyte degradable by the protease. The analyte is contacted with the sample. The degradation products of the analyte or the residual undegraded analyte is detected in a binding assay.Type: GrantFiled: February 23, 2007Date of Patent: May 3, 2011Assignee: Mologic LtdInventors: Paul James Davis, Mark James Davis, Mark Burnapp
-
Patent number: 7919248Abstract: The present invention is drawn to methods for modulating IL-13 expression and/or activity in a mammal comprising administering an effective amount of an agent which modulates the expression and/or activity of IL-9.Type: GrantFiled: April 25, 2008Date of Patent: April 5, 2011Assignee: Ligand Pharmaceuticals IncorporatedInventors: Yuhong Zhou, Jamila Louahed, Nicholas C. Nicolaides, Michael McLane, Roy C. Levitt
-
Patent number: 7915052Abstract: The present invention is related to immunoglobulin peptides that recognize a thermostable antigen from bovine blood. The invention also provides methods for determining the presence of bovine blood in a food sample or an animal feed sample.Type: GrantFiled: February 25, 2010Date of Patent: March 29, 2011Assignee: Florida State University Research Foundation, Inc.Inventor: Yun-Hwa Peggy Hsieh
-
Patent number: 7906290Abstract: An antibody for diagnosis or treatment of neuropsychiatric diseases, in particular schizophrenia, depression or bipolar affective disorders, is characterized in that the antibody recognizes misfolded specific proteins that can be assigned to one of the diseases, and a method for diagnosis by means of antibodies that bind to neuropsychiatric disease-specific proteins.Type: GrantFiled: February 11, 2005Date of Patent: March 15, 2011Inventors: Carsten Korth, S. Rutger Leliveld
-
Publication number: 20110059858Abstract: The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression level of the TREML-1 biomarker as an indication of the condition of the patient, alone or in combination with further sepsis markers.Type: ApplicationFiled: May 19, 2009Publication date: March 10, 2011Applicant: Pronota N.V.Inventors: Koen Kas, Griet Vanpoucke
-
Patent number: 7892757Abstract: An immunochemical method for the accurate measurement of the quantity of cytochrome c in a body fluid, in particular, blood, and a kit for the measurement. The quantity of cytochrome c can be measured accurately without being affected by any interfering substrate by reacting an antibody with cytochrome c in a buffer solution in an acidic range.Type: GrantFiled: April 17, 2006Date of Patent: February 22, 2011Assignee: Eisai R&D Management Co., Ltd.Inventor: Muneo Aoyama
-
Patent number: 7892770Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.Type: GrantFiled: August 24, 2007Date of Patent: February 22, 2011Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research CenterInventors: Boliang Cao (Brian), George F. Vande Woude, Beatrice S. Knudsen
-
Patent number: 7888002Abstract: It is an object of the present invention to provide a method for simply mixing two or more types of liquids in a porous carrier.Type: GrantFiled: September 29, 2008Date of Patent: February 15, 2011Assignee: Fujifilm CorporationInventors: Junichi Katada, Akira Wakabayashi
-
Patent number: 7888133Abstract: The invention relates to method of detecting autoantibodies from patients suffering from rheumatoid arthritis. To this end, according to the invention, at least two peptide units are used of which at least one peptide unit comprises a part not derived from (pro)filaggrin, fibrin, fibrinogen, vimentin, cytokeratin 1 and cytokeratin 9, and which peptide unit comprises the motif XG, and a peptide unit comprising the motif XnonG, wherein X is a citrulline or an analogue thereof, and nonG is an amino acid other than glycine.Type: GrantFiled: December 11, 2002Date of Patent: February 15, 2011Assignee: Stichting Voor De Technische WetenschappenInventors: Waltherus Jacobus Wilhelmus Van Venrooij, Jan Wouter Drijfhout, Martinus Adrianus Maria Van Boekel, Gerardus Jozef Maria Pruijn
-
Patent number: 7888040Abstract: The present invention provides immunoassays which are highly specific for detection in biological samples of methamphetamine and other drugs of abuse of the methamphetamine group such as ecstasy and other ecstasy class drugs. More particularly, competitive assays are provided comprising: (a) contacting said sample with (i) a pseudoephedrine/carrier conjugate in which pseudoephedrine is linked via its hydroxyl group to the carrier and (ii) an antibody which is capable of binding both one or more drugs of the methamphetamine group and said conjugate; and (b) determining whether the binding of said antibody to said conjugate is reduced by the presence of said sample, a reduction in binding being indicative that the sample contains a methamphetamine group drug.Type: GrantFiled: June 10, 2005Date of Patent: February 15, 2011Assignee: Concateno UK LimitedInventor: Ahmed Mohammed Taki Jehanli
-
Patent number: 7879562Abstract: A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to ME-5 (SEQ ID NO:3) polypeptide or a peptide comprising an epitope of ME-5 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.Type: GrantFiled: July 15, 2009Date of Patent: February 1, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: A. Said El Shami, Bruce Campbell, Dennis Sustarsic, Niver Sahakian
-
Patent number: 7871790Abstract: Based on the observation that exposure of cells or animals to anthrax lethal toxin results in activation of the intracellular enzyme caspase-1/IL-1 converting enzyme (ICE), which, in turn, leads to production and extracellular release of the cytokine substrates of ICE: interleukin 1 beta (IL-1?) and interleukin 18 (IL-18), disclosed herein are bioassays that can be used to determine the efficacy of a potential anthrax therapeutic agent and for screening test agents to identify anthrax therapeutic agents. Also disclosed herein are methods of diagnosing and treating anthrax infection.Type: GrantFiled: March 2, 2005Date of Patent: January 18, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Frucht, Ruth Cordoba-Rodriguez
-
Patent number: 7867723Abstract: Methods for detecting anti-lipidic particle antibodies and lipidic particles in cellular membranes for the diagnosis of diseases associated with antiphospholipid syndrome are disclosed. Kits or sets to put these methods of diagnosis into practice are disclosed. Methods for the therapeutic treatment of diseases associated with antiphospholipid syndrome are disclosed as well. In addition, methods for the detection of the diverse physiologic states of cells and kits useful for this are also disclosed.Type: GrantFiled: June 14, 2004Date of Patent: January 11, 2011Assignee: Escuela Nacional De Ciencias Biologicas, Del Instituto Politecnico NacionalInventors: Maria Isabel Baeza-Ramirez, José Leopoldo Aguilr-Faisal, Carlos Wong-Ramirez, Miguel Angel Ibáñez Hernández, Mónica Lara-Uc
-
Patent number: 7858071Abstract: The invention provides a method for diagnosing amyotrophic lateral sclerosis (ALS) in a subject, a method for assessing the effectiveness of a drug in treating ALS, and a method for determining the site of onset of ALS in a subject. Each method comprises (a) obtaining a sample from the subject, (b) analyzing the proteins in the sample by mass spectroscopy, and (c) determining a mass spectral profile for the sample. In some embodiments, the method comprises comparing the mass spectral profile of the sample to the mass spectral profile of a positive or a negative standard.Type: GrantFiled: October 25, 2004Date of Patent: December 28, 2010Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Robert P. Bowser, Srikanth Ranganathan
-
Patent number: 7846675Abstract: A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus, Orientia tsutsugamushi for the Karp, Kato and Gilliam strains has been produced. The invention is useful for detecting prior exposure to scrub typhus, screening for and/or identification of at least one infectious strain-similarity (i.e. a Karp-like, Kato-like or Gilliam-like strain) based on its strength of reaction toward a truncated protein and as a component in vaccine formulation sand production of immune globulins for passive prophylaxis and immunity in subjects.Type: GrantFiled: December 27, 2007Date of Patent: December 7, 2010Assignee: The United States of America as represented by the Secretary of the NavyInventors: Wei-Mei Ching, Daryl J. Kelly, Gregory A. Dasch
-
Patent number: 7842513Abstract: This invention provides methods and compositions for testing for pregnancy and non-pregnancy in ungulates and non-hoofed ruminates. The tests provided by this invention are useful during a time that coincides with the estrus cycle during which breeding occurs or the first estrus cycle after breeding of a non-pregnant animal. The tests provided by this invention are useful in estrus and ovulation synchronization programs, with pregnancy testing useful at a time allowing for resynchronization of non-pregnant animals within the first estrus cycle. The tests provided by this invention assay for the presence, absence, or level of a selected IFN-?-induced protein in a sample from a female animal. The tests of this invention are useful for testing cells, blood, plasma, serum, cells, milk, nasal secretions, ocular secretions, vaginal secretions, urine, and saliva samples. The tests provided by this invention are immunoassays.Type: GrantFiled: May 2, 2003Date of Patent: November 30, 2010Assignees: AspenBio Pharma, Inc., University of WyomingInventors: Mark Colgin, Diane Newman, Cathy Landmann, Jay W. Roth, Roger Hurst, Thomas R. Hansen, Kathleen Jeanette Austin
-
Patent number: 7842500Abstract: An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swarn tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.Type: GrantFiled: March 31, 2006Date of Patent: November 30, 2010Assignee: Seikagaku CorporationInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto
-
Patent number: 7842463Abstract: There is disclosed a method of diagnosing early stage renal impairment in humans, characterized by the following steps: measuring the amount of apoA-IV in a body liquid or tissue sample of a human, and comparing the measured amount of apoA-IV with a reference value.Type: GrantFiled: July 23, 2002Date of Patent: November 30, 2010Assignee: Vitateq Biotechnology GmbhInventor: Florian Kronenberg
-
Patent number: 7829294Abstract: The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A?-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.Type: GrantFiled: December 27, 2005Date of Patent: November 9, 2010Assignee: Daiichi Pure Chemicals Co., Ltd.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Osamu Miyazaki, Kyoko Tanaka, Akiko Suzuki
-
Patent number: 7820393Abstract: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and optionally one or more of a selection of non-whole parathyroid hormone peptide fragments that may or may not function as a parathyroid hormone antagonists. By either comparing values or using independently the value of either the one or more of a selection of non-whole parathyroid hormone peptide fragments, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.Type: GrantFiled: July 10, 2003Date of Patent: October 26, 2010Assignee: Scantibodies Laboratory, Inc.Inventors: Thomas L. Cantor, Ping Gao
-
Patent number: 7820444Abstract: Method as well a kit for the performance of the method for the investigation of biological samples from a mammal for at least one component, wherein the method includes the following steps: (a) Administering at least one marker substance to a mammal; (b) Waiting for a length of time which is sufficient for the at least one marker substance to reach the location of sample removal; (c) Removing a biological sample from the mammal; (d) Investigating the biological sample for the presence and/or amount of at least one marker substance or a derivative thereof; and, if the at least one marker substance or the derivative thereof is detectable in the biological sample; (e) Investigating the biological sample for an analyte.Type: GrantFiled: March 14, 2002Date of Patent: October 26, 2010Inventors: Ruprecht Keller, Gisela Gauchel